Delivery Order SPE2DB20D3101-SPE2DB24FRNL2

Award Date 6/24/24
Potential Completion Date 7/16/24
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,587.82 firm fixed-price delivery order is for the supply of the drug Envarsus XR 1 mg tablets, with a completion date of November 22, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the delivery of Envarsus XR 1 mg tablets. The contract, valued at $1,216.11, is a firm fixed-price delivery order with a period of performance through July 5, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025....
This federal contract award, valued at $1,621.48, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is a delivery order for the product "ENVARSUS XR 1 MG TABLET 100S" and has an ultimate completion date of August 20, 2024. The contract is a firm fixed price arrangement and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,711.95 firm fixed-price delivery order is for the supply of Envarsus XR 4 mg tablets, a medication used in organ transplant patients. The contract has an ultimate completion date of May 30, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $1,516.32, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of Envarsus XR 1 mg tablets and is a firm fixed-price delivery order with a completion date of December 11, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,711.95 firm fixed-price delivery order is for the supply of ENVARSUS XR 4 MG TABLET 100S, a pharmaceutical product. The contract has an ultimate completion date of March 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the delivery of Envarsus XR 1 mg tablets. The contract, valued at $1,465.68, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to serve the Department of Defense (DoD) and other government agencies. The award is a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, which has a ceiling value of up to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Envarsus XR 1 mg tablets. The $2,577.72 firm-fixed-price contract has an ultimate completion date of April 3, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a broad range of pharmaceutical products and medical supplies...
This federal contract award, valued at $1,615.33, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Envarsus XR 4 mg tablets, a specialty pharmaceutical product, with a period of performance through November 18, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The $1,216.11 firm-fixed-price delivery order is for the pharmaceutical product Envarsus XR 1 mg tablet, with a completion date of July 8, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB24FRNL2
    Delivery Order

This federal contract award, valued at $1,216.11, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Envarsus XR 1 mg tablets, a pharmaceutical product, and has a completion date of July 16, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

The contract award was not designated with a set-aside requirement, indicating open competition.

Generated 2/27/25, 12:01 PM